Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05729607 · ClinicalTrials.gov registry record · NA

Vertical Soft Tissue Augmentation With CTG vs ADM

A NA study of Implant Complication, sponsored by Harvard Medical School (HMS and HSDM).

Recruiting
Registry status
NA
Development phase
28
Enrollment target
1
Study location

NCT05729607: Recruiting NA study of Implant Complication, sponsored by Harvard Medical School (HMS and HSDM).

NCT05729607 is a NA study of Implant Complication that is actively recruiting participants, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 28 participants, below the 90-participant average among 3 other Implant Complication trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05729607, a NA study of Implant Complication, is actively recruiting participants, sponsored by Harvard Medical School (HMS and HSDM).

RECRUITING
Registry status
NA
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

Primary Outcome

Change of the depth of the Soft tissue dehiscence (vertical measurement of the complication, in relation to the level of the cemento-enamel junction of the contralateral homologous tooth) at 12 months compared to baseline (expressed in millimeters)

Conditions Studied

Interventions

  • PROCEDURE Vertical soft tissue augmentation

Study Locations (1)

Massachusetts

  • Harvard School of Dental Medicine - Boston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-05-26
Est. Completion 2027-11-27
Phase NA

What NCT05729607 shows while recruiting

NCT05729607 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 90-participant average among 3 other Implant Complication trials with a reported enrollment target (69% lower).

The record links to 1 condition, with Implant Complication appearing as the primary indexed condition, and to 1 intervention - of which Vertical soft tissue augmentation is the first listed.

NCT05729607 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05729607 about?

NCT05729607 is a clinical study titled "Vertical Soft Tissue Augmentation With CTG vs ADM". The study aims at comparing two different approaches for vertical soft tissue augmentation at implant sites exhibiting soft tissue dehiscences: autogenous connective tissue graft vs acellular dermal matrix + enamel matrix derivative

What is the current status of trial NCT05729607?

This trial is currently recruiting. It is a NA study. The enrollment target is 28 participants. The study started on 2023-05-26. Estimated completion is 2027-11-27.

What conditions does trial NCT05729607 study?

This clinical trial studies the following conditions: Implant Complication.

What interventions are being tested in trial NCT05729607?

The interventions under investigation include: Vertical soft tissue augmentation (PROCEDURE).

Who is sponsoring clinical trial NCT05729607?

This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05729607 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Implant Complication

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03471117 · 28 participants · Phase 4

    Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

  • NCT03523975 · 28 participants · Phase 1

    Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

  • NCT03608631 · 28 participants · Phase 1

    iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation

  • NCT03810651 · 28 participants · Early Phase 1

    Pencil Beam Scanning in Patients With Renal Tumors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05729607, the US trial registry maintained by the National Library of Medicine. NCT05729607 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.